U.S. markets close in 6 hours 12 minutes

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5697+0.0195 (+3.54%)
As of 09:48AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.5502
Bid0.5530 x 900
Ask0.5650 x 1100
Day's Range0.5530 - 0.5761
52 Week Range0.3600 - 4.0800
Avg. Volume1,991,673
Market Cap83.393M
Beta (5Y Monthly)-0.29
PE Ratio (TTM)N/A
EPS (TTM)-1.1000
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 28, 2014
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VERU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Veru Inc.
    Daily – Vickers Top Buyers & Sellers for 02/22/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

    MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the formation of a new Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when com

  • Zacks

    After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)

    The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  • Insider Monkey

    Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript

    Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript February 8, 2024 Veru Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Veru Inc. Investor Conference Call. [Operator Instructions] Please note, this […]